Infexn Laboratories Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 06-07-2024
- Paid Up Capital ₹ 1.00 M
as on 06-07-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.20 M
as on 06-07-2024
- Revenue -19.75%
(FY 2023)
- Profit -143.96%
(FY 2023)
- Ebitda -92.02%
(FY 2023)
- Net Worth -4.26%
(FY 2023)
- Total Assets -5.87%
(FY 2023)
About Infexn Laboratories
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹7.20 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sonal Bangde, Anil Nair, and Sachin Bhole serve as directors at the Company.
- CIN/LLPIN
U74999MH2013PTC241460
- Company No.
241460
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2013
- Date of AGM
11 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Infexn Laboratories?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sachin Bhole  | Director | 28-Mar-2013 | Current |
| Sonal Bangde | Director | 28-Mar-2013 | Current |
| Anil Nair | Director | 28-Mar-2013 | Current |
Financial Performance of Infexn Laboratories.
Infexn Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.75% decrease. The company also saw a substantial fall in profitability, with a 143.96% decrease in profit. The company's net worth dipped by a decrease of 4.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Infexn Laboratories?
In 2023, Infexn Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Labguru Healthcare Private LimitedActive 13 years 5 monthsAnil Nair and Sachin Bhole are mutual person
Charges (Loans)
₹0
₹7.20 M
Charges Breakdown by Lending Institutions
- Others : 0.72 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Jun 2018 | Others | ₹3.50 M | Satisfied |
| 21 Mar 2018 | Others | ₹2.20 M | Satisfied |
| 08 Mar 2017 | Others | ₹1.50 M | Satisfied |
How Many Employees Work at Infexn Laboratories?
Infexn Laboratories has a workforce of 129 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Infexn Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Infexn Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
